These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 22091601)

  • 21. Current and novel therapeutic molecules and targets in Alzheimer's disease.
    Kumar A; Nisha CM; Silakari C; Sharma I; Anusha K; Gupta N; Nair P; Tripathi T; Kumar A
    J Formos Med Assoc; 2016 Jan; 115(1):3-10. PubMed ID: 26220908
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Medical Clinics of North America. Early diagnosis and intervention in predementia Alzheimer's disease. Preface.
    Molinuevo JL; Cummings JL; Dubois B; Scheltens P
    Med Clin North Am; 2013 May; 97(3):xiii-xv. PubMed ID: 23642584
    [No Abstract]   [Full Text] [Related]  

  • 23. Toward the validation of functional neuroimaging as a potential biomarker for Alzheimer's disease: implications for drug development.
    Pupi A; Mosconi L; Nobili FM; Sorbi S
    Mol Imaging Biol; 2005; 7(1):59-68. PubMed ID: 15912277
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Endocannabinoid System Biomarkers in Alzheimer's Disease.
    Ferreira PCL; Bellaver B; Povala G; Brum WS; Tissot C; Badji A; Sloan ME; Benedet AL; Rosa-Neto P; Ashton NJ; Pascoal TA; Leuzy A; Zimmer ER
    Cannabis Cannabinoid Res; 2023 Feb; 8(1):77-91. PubMed ID: 36394442
    [No Abstract]   [Full Text] [Related]  

  • 25. Use of biomarkers in clinical trials of Alzheimer disease: from concept to application.
    Wu L; Rosa-Neto P; Gauthier S
    Mol Diagn Ther; 2011 Dec; 15(6):313-25. PubMed ID: 22188635
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Alzheimer's disease therapeutic trials: EU/US Task Force report on recruitment, retention, and methodology.
    Vellas B; Hampel H; Rougé-Bugat ME; Grundman M; Andrieu S; Abu-Shakra S; Bateman R; Berman R; Black R; Carrillo M; Donohue M; Mintun M; Morris J; Petersen R; Thomas RG; Suhy J; Schneider L; Seely L; Tariot P; Touchon J; Weiner M; Sampaio C; Aisen P;
    J Nutr Health Aging; 2012 Apr; 16(4):339-45. PubMed ID: 22499454
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Emerging concepts towards a translational framework in Alzheimer's disease.
    Cozachenco D; Zimmer ER; Lourenco MV
    Neurosci Biobehav Rev; 2023 Sep; 152():105246. PubMed ID: 37236385
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Alzheimer's disease: neuropathologic findings and recent advances in imaging.
    Norfray JF; Provenzale JM
    AJR Am J Roentgenol; 2004 Jan; 182(1):3-13. PubMed ID: 14684506
    [No Abstract]   [Full Text] [Related]  

  • 29. Lessons learned from failed and discontinued clinical trials for the treatment of Alzheimer's disease: future directions.
    Carlsson CM
    J Alzheimers Dis; 2008 Oct; 15(2):327-38. PubMed ID: 18953117
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives.
    Hampel H; Frank R; Broich K; Teipel SJ; Katz RG; Hardy J; Herholz K; Bokde AL; Jessen F; Hoessler YC; Sanhai WR; Zetterberg H; Woodcock J; Blennow K
    Nat Rev Drug Discov; 2010 Jul; 9(7):560-74. PubMed ID: 20592748
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Early risk assessment for Alzheimer's disease.
    Carrillo MC; Blackwell A; Hampel H; Lindborg J; Sperling R; Schenk D; Sevigny JJ; Ferris S; Bennett DA; Craft S; Hsu T; Klunk W
    Alzheimers Dement; 2009 Mar; 5(2):182-96. PubMed ID: 19328456
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical Trial Endpoints and Their Clinical Meaningfulness in Early Stages of Alzheimer's Disease.
    Cohen S; Cummings J; Knox S; Potashman M; Harrison J
    J Prev Alzheimers Dis; 2022; 9(3):507-522. PubMed ID: 35841252
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Disease modifying trials in Alzheimer's disease: perspectives for the future.
    Vellas B; Coley N; Andrieu S
    J Alzheimers Dis; 2008 Oct; 15(2):289-301. PubMed ID: 18953115
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Testing the right target and right drug at the right stage.
    Sperling RA; Jack CR; Aisen PS
    Sci Transl Med; 2011 Nov; 3(111):111cm33. PubMed ID: 22133718
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Assessment of functional changes in Alzheimer's disease.
    Gauthier L; Gauthier S
    Neuroepidemiology; 1990; 9(4):183-8. PubMed ID: 2215842
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Biomarkers in Alzheimer's disease drug development.
    Blennow K
    Nat Med; 2010 Nov; 16(11):1218-22. PubMed ID: 21052077
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Biological markers of Alzheimer's disease.
    Klunk WE
    Neurobiol Aging; 1998; 19(2):145-7. PubMed ID: 9558151
    [No Abstract]   [Full Text] [Related]  

  • 38. Biomarkers for Alzheimer's disease: ready for the next step.
    Rosenberg PB; Hillis AE
    Brain; 2009 Aug; 132(Pt 8):2002-4. PubMed ID: 19617196
    [No Abstract]   [Full Text] [Related]  

  • 39. On understanding Alzheimer's disease.
    Raskin DE
    Am J Psychiatry; 1985 Oct; 142(10):1225. PubMed ID: 4037140
    [No Abstract]   [Full Text] [Related]  

  • 40. Neuro-imaging: structural and functional imaging.
    Frisoni GB
    J Nutr Health Aging; 2009 Apr; 13(4):348-9. PubMed ID: 19300876
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.